We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Vircell S.L.

Vircell is a biotechnology company specializing in the development and production of ready-to-use reagents for the di... read more Featured Products: More products

Download Mobile App




Vircell Showcases Its Powerful Automation System and Immunoassay Testing Kits at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
Vircell (Granada, Spain) exhibited its powerful automation system and immunoassay testing kits at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 15-18 November in Düsseldorf, Germany.

Vircell is a microbial biotechnology company which develops, manufactures and markets ready-to-use kits for the diagnosis of esoteric infectious diseases. More...
It is specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology.

At MEDICA 2021, Vircell presented VIRCLIA, its powerful automation system with a built-in reader, intelligent racks and intuitive software. The VIRCLIA automation system offers 192 patient sample positions and fully-automated reader options (EIA or CLIA+EIA). It features a probe-mounted camera for real-time process monitoring and remote diagnostics, along with a built-in barcode reader for streamlined loading and lower sample tracking errors.

Among the immunoassay testing kits showcased by Vircell at the event was the Chlamydia ELISA indirect immunoenzyme assay to test antibodies against chlamydia in human serum/plasma which is suitable for automated ELISA systems. Vircell also highlighted Pneumobact IFA, an indirect immunofluorescent assay kit to simultaneously test IgG or IgM antibodies against the main ethiological bacterial agents causing respiratory tract infections: Legionella pneumophila sero group 1, Mycoplasma pneumoniae, Coxiella burnetii, Chlamydophila pneumoniae and Chlamydophila psittaci. The kit enables simultaneous detection of the main bacteria causing atypical pneumonia and easy results reading.

Related Links:
Vircell


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.